All the news

Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ...

More than one in ten HIV-positive people in the large EuroSIDA cohort who were cured of hepatitis C were reinfected within two years, according to a report last month at ...

Hepatitis C co-infection does not increase the risk of cardiovascular disease or non-AIDS cancers in people with HIV, an analysis of the large EuroSIDA cohort published in Clinical Infectious Diseases has found. ...

People with hepatitis C who received interferon-based treatment were less likely to develop Parkinson’s disease, a large study from Taiwan has concluded. The results, published in JAMA Neurology, add to the evidence ...

Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ...

Treatment with sofosbuvir/ledipasvir (Harvoni) was well tolerated and cured all pregnant women with hepatitis C virus (HCV), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) ...

Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ...

Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ...